The FDA label includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, contraindicating use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
doi: 10.1159/000335468 41
They increase oxidative stress, shorten telomeres faster, impair GH signaling, and blunt the cellular response to peptide therapy
Persistent or worsening symptoms such as fever, chills, or lightheadedness
In this context, postbiotics are more plausibly positioned not as primary weight-loss interventions, but as nutritional strategies that may be continued after GLP-1based pharmacotherapy to support metabolic stability, mitigate weight regain, and preserve lean mass during the post-treatment phase ( From a clinical nutrition perspective, postbiotics should not be positioned as weight-loss agents, nor as substitutes for pharmacological GLP-1 receptor agonists